Eurofins Viracor Diagnostics Launches Combined Test For COVID-19, Influenza, And RSV As The Flu Season Approaches

 

LEE'S SUMMIT, Mo., Nov. 18, 2020 /PRNewswire/ -- Eurofins Viracor, a leading infectious disease testing laboratory for more than 35 years, announces the launch  of several combined tests which detect COVID-19, influenza A/B, and respiratory syncytial virus (RSV). The combined SARS-CoV-2 Plus Flu A/B and RSV tests are intended for the qualitative detection of SARS-CoV-2 and the quantitative detection of Influenza A, Influenza B, and RSV.

With flu season underway and US COVID-19 cases reaching 10 million, these combined tests will play an important role for extended care facilities, employers, schools, and healthcare systems by distinguishing between multiple respiratory pathogens that exhibit overlapping symptoms including COVID-19 and Flu.

The combined COVID-19 and Flu test is now available and can also be ordered as individual tests. The combined COVID-19, Flu, and RSV test is anticipated to launch on December 7.

Since the onset of the pandemic, Eurofins Viracor has continued its leadership in the diagnostic testing effort to tackle this health crisis by being one of the first commercial laboratories to receive EUA of the SARS-CoV-2 RT-PCR test and continued capacity investment to support an average turnaround time of less than 24 hours. Eurofins Viracor's innovative, highly accurate tests support healthcare systems, nursing homes, sports organizations, employers, and schools. Eurofins' innovative COVID-19 assays include: EUA-authorized At-Home COVID-19 PCR Test Kit, pooled, antibody, wastewater, worn-mask, and saliva tests.

COVID-19 testing plays a critical role in therapeutics population surveillance, clinical trials, and forthcoming vaccination implementation. Eurofins continues to support the scientific community's pursuit of new COVID-19 vaccines and therapeutics during discover, novel assay development, and throughout all phases of clinical trials.

ABOUT VIRACOR

With over 30 years of specialized expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Viracor Eurofins is committed to helping medical professionals, transplant teams, reference laboratories and biopharmaceutical companies get results faster, when it matters most. Viracor is passionate about delivering value to its clients by providing timely, actionable information, never losing sight of the connection between the testing it performs and the patients it ultimately serves. Viracor is a 100 percent subsidiary of Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services. For more information, please visit https://www.eurofins.com/ and https://www.viracor-eurofins.com/.

About Eurofins – the global leader in bio-analysis

Eurofins Scientific, through its subsidiaries (hereinafter "Eurofins" or "the Group"), believes it is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing. With over 50,000 staff across a network of more than 900 independent companies in over 50 countries generally specialised by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services. The Group's objective is to provide its customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.

As one of the most innovative and quality-oriented international groups in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/eurofins-viracor-diagnostics-launches-combined-test-for-covid-19-influenza-and-rsv-as-the-flu-season-approaches-301176184.html

SOURCE Viracor Eurofins

 
 
Company Codes: EuronextParis:ERF, OTC-PINK:ERRFY
 

Back to news